What is it about?
Any mutation of KRAS, BRAF or PIK3CA indicates a higher risk of recurrence or metastasis in stage II colorectal cancer, and that closer follow-up or active adjuvant chemotherapy are urgently needed.
Featured Image
Read the Original
This page is a summary of: Investigation of correlation between mutational status in key EGFR signaling genes and prognosis of stage II colorectal cancer, Future Oncology, July 2017, Taylor & Francis,
DOI: 10.2217/fon-2017-0040.
You can read the full text:
Contributors
The following have contributed to this page
